JP2021523913A5 - - Google Patents
Info
- Publication number
- JP2021523913A5 JP2021523913A5 JP2020564167A JP2020564167A JP2021523913A5 JP 2021523913 A5 JP2021523913 A5 JP 2021523913A5 JP 2020564167 A JP2020564167 A JP 2020564167A JP 2020564167 A JP2020564167 A JP 2020564167A JP 2021523913 A5 JP2021523913 A5 JP 2021523913A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- heavy chain
- light chain
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023183225A JP7680514B2 (ja) | 2018-05-16 | 2023-10-25 | Ｎｋｇ２ｄ、ｃｄ１６、及び線維芽細胞活性化タンパク質と結合するタンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862672299P | 2018-05-16 | 2018-05-16 | |
| US62/672,299 | 2018-05-16 | ||
| PCT/US2019/032582 WO2019222449A1 (en) | 2018-05-16 | 2019-05-16 | Protein binding nkg2d, cd16 and a fibroblast activation protein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023183225A Division JP7680514B2 (ja) | 2018-05-16 | 2023-10-25 | Ｎｋｇ２ｄ、ｃｄ１６、及び線維芽細胞活性化タンパク質と結合するタンパク質 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021523913A JP2021523913A (ja) | 2021-09-09 |
| JP2021523913A5 true JP2021523913A5 (https=) | 2022-05-20 |
| JPWO2019222449A5 JPWO2019222449A5 (https=) | 2022-05-20 |
| JP7494129B2 JP7494129B2 (ja) | 2024-06-03 |
Family
ID=68540990
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564167A Active JP7494129B2 (ja) | 2018-05-16 | 2019-05-16 | Ｎｋｇ２ｄ、ｃｄ１６、及び線維芽細胞活性化タンパク質と結合するタンパク質 |
| JP2023183225A Active JP7680514B2 (ja) | 2018-05-16 | 2023-10-25 | Ｎｋｇ２ｄ、ｃｄ１６、及び線維芽細胞活性化タンパク質と結合するタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023183225A Active JP7680514B2 (ja) | 2018-05-16 | 2023-10-25 | Ｎｋｇ２ｄ、ｃｄ１６、及び線維芽細胞活性化タンパク質と結合するタンパク質 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210363261A1 (https=) |
| EP (1) | EP3793605A4 (https=) |
| JP (2) | JP7494129B2 (https=) |
| KR (1) | KR20210010508A (https=) |
| CN (1) | CN112423788A (https=) |
| AU (2) | AU2019271263A1 (https=) |
| BR (1) | BR112020023299A2 (https=) |
| CA (1) | CA3100234A1 (https=) |
| MX (1) | MX2020012273A (https=) |
| SG (1) | SG11202011139YA (https=) |
| WO (1) | WO2019222449A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201907299XA (en) | 2017-02-08 | 2019-09-27 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| IL268755B2 (en) | 2017-02-20 | 2025-12-01 | Dragonfly Therapeutics Inc | Proteins that bind her2, nkg2d, and cd16 |
| EA202091887A1 (ru) | 2018-02-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры |
| DK3749346T3 (da) | 2018-02-08 | 2024-09-09 | Dragonfly Therapeutics Inc | Antistof variable domænekombinationer rettet mod nkg2d-receptoren |
| WO2019164930A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| WO2020033630A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| US12378318B2 (en) | 2018-08-08 | 2025-08-05 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and a tumor-associated antigen |
| MX2022013944A (es) | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| US20240115670A1 (en) | 2021-01-27 | 2024-04-11 | Georgetown University | Fibroblast activation protein modulation to alter immune cell migration and tumor infiltration |
| JP2024508894A (ja) | 2021-03-03 | 2024-02-28 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法 |
| EP4311557A1 (en) * | 2022-07-26 | 2024-01-31 | Oncomatryx Biopharma, S.L. | Fap-targeted antibody-drug conjugates |
| AR134514A1 (es) | 2023-12-01 | 2026-01-21 | Gilead Sciences Inc | Proteína de fusión anti-fap-ligera y uso de esta |
| WO2025244097A1 (ja) * | 2024-05-23 | 2025-11-27 | オプティアム・バイオテクノロジーズ株式会社 | 改良型抗ＦＡＰα－キメラ抗原受容体 |
| CN119265201A (zh) * | 2024-08-23 | 2025-01-07 | 中国人民解放军海军军医大学第一附属医院 | 编码基因、蛋白、表达il-15的nkg2dl-fap双靶点car-nk细胞及其构建方法和用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006301163B2 (en) * | 2005-10-14 | 2012-02-23 | Innate Pharma | Compositions and methods for treating proliferative disorders |
| KR101615935B1 (ko) * | 2007-12-14 | 2016-04-28 | 노보 노르디스크 에이/에스 | 인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도 |
| US9273136B2 (en) * | 2008-08-04 | 2016-03-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fully human anti-human NKG2D monoclonal antibodies |
| UY32808A (es) | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| ES2534085T3 (es) * | 2009-08-17 | 2015-04-17 | Roche Glycart Ag | Inmunoconjugados dirigidos |
| HUE036077T2 (hu) * | 2010-08-13 | 2018-06-28 | Roche Glycart Ag | Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások |
| LT2794658T (lt) * | 2011-12-19 | 2017-05-10 | Synimmune Gmbh | Bispecifinė antikūno molekulė |
| GB201402006D0 (en) * | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
| WO2016115274A1 (en) * | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| DK3313876T3 (da) * | 2015-06-23 | 2025-04-22 | Innate Pharma | Multispecifikke antigenbindende proteiner |
| MA43874A (fr) | 2016-01-13 | 2018-11-21 | Compass Therapeutics Llc | Constructions de liaison à l'antigène immunomodulateur multispécifique |
| WO2017165464A1 (en) | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| JP2018035137A (ja) * | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ | 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用 |
| SG11201907299XA (en) * | 2017-02-08 | 2019-09-27 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| AU2018318698A1 (en) * | 2017-08-16 | 2020-02-20 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16, and EGFR, HLA-E CCR4, or PD-L1 |
-
2019
- 2019-05-16 WO PCT/US2019/032582 patent/WO2019222449A1/en not_active Ceased
- 2019-05-16 US US17/055,792 patent/US20210363261A1/en not_active Abandoned
- 2019-05-16 MX MX2020012273A patent/MX2020012273A/es unknown
- 2019-05-16 SG SG11202011139YA patent/SG11202011139YA/en unknown
- 2019-05-16 EP EP19803947.1A patent/EP3793605A4/en active Pending
- 2019-05-16 CN CN201980047481.2A patent/CN112423788A/zh active Pending
- 2019-05-16 KR KR1020207035733A patent/KR20210010508A/ko not_active Ceased
- 2019-05-16 CA CA3100234A patent/CA3100234A1/en active Pending
- 2019-05-16 BR BR112020023299-8A patent/BR112020023299A2/pt unknown
- 2019-05-16 AU AU2019271263A patent/AU2019271263A1/en not_active Abandoned
- 2019-05-16 JP JP2020564167A patent/JP7494129B2/ja active Active
-
2023
- 2023-10-25 JP JP2023183225A patent/JP7680514B2/ja active Active
-
2026
- 2026-02-26 AU AU2026201454A patent/AU2026201454A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021523913A5 (https=) | ||
| JP2021534096A5 (https=) | ||
| JP2025111463A5 (https=) | ||
| JP2020522474A5 (https=) | ||
| JP2021035388A5 (ja) | Ｃａｉｘ、ａｎｏ１、メソテリン、ｔｒｏｐ２またはクローディン−１８．２を標的にする多重特異性結合タンパク質 | |
| JP2021523140A5 (https=) | ||
| JP2020510653A5 (ja) | Ｃｅａを標的にする多重特異性結合タンパク質 | |
| JP2023123726A5 (https=) | ||
| JP2020521448A5 (https=) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2019536430A5 (https=) | ||
| JP2020508997A5 (https=) | ||
| JPWO2019222449A5 (https=) | ||
| JP2021533159A5 (https=) | ||
| JP2013527761A5 (https=) | ||
| JP2018507188A5 (https=) | ||
| JP2020514277A5 (https=) | ||
| JP2021522347A5 (https=) | ||
| JPWO2020033587A5 (https=) | ||
| RU2019129511A (ru) | Белки, связывающие gd2, nkg2d и cd16 | |
| JP2024016024A5 (https=) | ||
| JPWO2021138467A5 (https=) | ||
| JP2021511387A5 (https=) | ||
| JP2024020436A5 (https=) | ||
| JPWO2020033664A5 (https=) |